Prostate cancer - cabazitaxel (TA255)
Fast, easy summary view of NICE guidance on 'prostate cancer'
NICE does not recommend cabazitaxel for people with hormone-refractory metastatic prostate cancer who have had docetaxel.
Why has NICE said this?
NICE looks at how well treatments work, and also at how well they work in relation to how much they cost the NHS. NICE applies special considerations to treatments that can extend the lives of people who are nearing the end of their life. Cabazitaxel does not provide enough benefit to patients to justify its high cost even when the special considerations were applied, so NICE did not recommend it.
This guidance has been incorporated into the following NICE Pathways, along with other related guidance and products.
Visit the NICE Pathway: prostate cancer
- None found
This page was last updated: 07 September 2012
- Web format
- Full Guidance (PDF)
- TA255 Cabazitaxel ar gyfer canser metastatig y brostad nad yw'n ymateb mwyach i driniaeth i atal hormonau ar ôl cael triniaeth docetaxel: deall canllawiau NICE (fformat MS Word)
Information for the public
Implementation tools and resources
See this guidance in practice
The summary of the key recommendations in the guidance written for patients, carers and those with little medical knowledge and may be used in local patient information leaflets.
Quick Reference Guide
The quick reference guide presents recommendations for health professionals
The published NICE clinical guidance, contains the recommendations for health professionals and NHS bodies.
The published full clinical guidance for specialists with background, evidence, recommendations and methods used.